Condition
Osimertinib
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Not Yet Recruiting1
Active Not Recruiting1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07491211Active Not Recruiting
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
NCT06818955Phase 2Not Yet Recruiting
Orlistat Overcoming Third-generation EGFR-TKI Resistance
NCT05458726Phase 2Unknown
Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC
Showing all 3 trials